INTRODUCTION
============

Alzheimer's disease (AD) is the most common form of dementia. The dramatic increase of life expectancy has resulted in an increasing number of patients with AD, imposing social and economic burden ([@B2]). The neuropathological hallmarks of the disease include accumulation of senile plaques, composed of β-amyloid (Aβ), and neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau protein. There is evidence supporting that Aβ initiates the pathogenesis of AD ([@B97]; [@B8]). However, the failure of clinical trials of "anti-Aβ" therapies indicates that the intervention should be applied earlier, because Aβ deposition commences decades before the development of clinical symptoms of AD ([@B18]; [@B60]).

Interestingly, a prospective cohort study suggested that use of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, which are widely prescribed for the treatment of hypercholesterolemic patients ([@B37]), decreases the incidence of AD by half. However, controversy exists regarding whether statins have therapeutic effects on AD. In this review, the potential effects of statins against AD are addressed by drawing upon previous basic and clinical studies. Statin use from midlife could prevent AD.

DYSLIPIDEMIA, AD, AND STATINS
=============================

The first statin, named "compactin," was discovered and isolated from microorganisms by a research team led by Dr. Akira Endo at Sankyo Co. in 1972 ([@B37]). His discovery initially suffered from the limitations of animal studies, because rodents were resistant to cholesterol reduction by statins ([@B36]). Dozens of studies using larger animals, like chicken, dog, and monkey, and a clinical study in familial hyperlipidemia patients showed that this statin reduces plasma low-density lipoprotein (LDL)-cholesterol level ([@B94]). Today, several statins are now in clinical use. Statins reduce cholesterol level via the inhibition of HMG-CoA reductase in hepatic cells. Sterol regulatory element-binding proteins (SREBPs) sense this change in cholesterol level, with a subsequent increase in their LDL receptor (LDLR) expression to uptake serum LDL cholesterol in order to compensate for the reduced cellular cholesterol content ([@B44]). Then, clinical studies have shown that statins prevent cardiovascular and cerebrovascular events ([@B145]; [@B24]; [@B179]; [@B49]) by reducing plasma cholesterol level ([@B3]; [@B30]) and regulating an isoprenoid pathway ([@B33]; [@B142]; [@B191]). Of note, the preventative effects could be more evident in middle age ([@B145], [@B144]; [@B49]).

CLINICAL STUDIES OF STATINS AND AD
----------------------------------

It is conceivable that statins prevent strokes, and thereby reduce the incidence of vascular dementia. However, further studies are required to clarify whether statins are effective to prevent AD. Firstly, two case--control studies supported the preventive effect of statins on AD ([@B63]; [@B181]), whereas the results of subsequent studies including prospective studies are controversial ([@B49]; [@B144]; [@B189]; [@B34]; [@B123]; [@B190]; [@B155]; [@B48]; [@B42]; [@B136]; [@B12]). Two recent randomized clinical studies enrolling around 400 mild-to-moderate AD patients have failed to show benefits of atorvastatin and simvastatin on cognitive function ([@B42]; [@B136]). Although these two randomized studies could refute the beneficial effects of statins on disease progression in AD patients, there were several limitations including the duration of intervention (18-month period) and the selection of subjects such as the exclusion of AD patients requiring treatment for dyslipidemia with lipid-lowering agents. On the other hand, several prospective studies indicate that statins could prevent the onset of AD ([@B63]; [@B155]; [@B48]; [@B12]). Follow-up period and cohort size of such supportive prospective studies are relatively longer and larger: over 6 years of follow-up and more than 1000 subjects enrolled. A recent meta-analysis by [@B183] also showed preventive effects of statins on AD. Of note, several reports indicated preventive effects of statins on AD only when they included relatively young subjects ([@B128]; [@B84], [@B86]). Taken together, these results of previous clinical studies indicate that the preventive effects and therapeutic effects against AD should be separately considered to elucidate the effects of statins against AD. Such idea corresponds with current understanding of "anti-Aβ" therapies: once clinical symptoms develop, other mechanisms would be required to treat AD ([@B54]; [@B18]). Therefore, possible benefits of statins against AD might be obtained if administered decades before the onset of the disease.

DIFFERENCES AMONG STATINS
-------------------------

One important aspect to consider in the effects of statins is their pharmacodynamics and permeability into the brain ([@B20]). Brain-permeable statins, such as simvastatin and lovastatin, might readily act on neurons and glia in the brain, and exert neuroprotective effects including Aβ-lowering effects ([@B41]; [@B149]). However, controversy exists regarding whether brain-permeable statins could be beneficial for AD ([@B181]; [@B6]). Among the studies showing preventive effects of statins on AD, only sub-analysis in the Ginkgo Evaluation of Memory Study reported that lipophilic statins tended to reduce the risk of dementia more than did hydrophilic statins ([@B12]). Notably, in the Rotterdam study, which showed a risk reduction of AD by statins, there was no difference in this beneficial effect between hydrophilic and lipophilic statins ([@B48]). Although the results of these studies may suffer limitations of small numbers for distinguishing hydrophilic and lipophilic statin users, the results of the latter prospective study suggested that the possible preventive effects of statins on AD might be due to the common mechanism of action of statins rather than the specific mechanism of action of brain-permeable statins. A recent review by [@B143] discussed the difficulty in attributing the protective effects of statins to specific brain-permeable statins, by pointing out the existence of several confounding effects, including the prescribed dosage, pattern and duration, statistical power, and genetic risks.

NON-GENETIC RISK FACTORS, AD, AND STATINS
=========================================

Non-genetic risk factors for AD include age, gender, physical activity, obesity, midlife hypertension, and diabetes mellitus. Meta-analyses have shown that the odds ratio of women to develop AD relative to men is 1.56 (95% CI 1.16--2.10; [@B65]). Thus far, no clinical report has recognized the gender-specific beneficial effect of statins on AD. A very high dose of lovastatin of 100 mg/kg/day, equal to around 100 times the human dose, increased Aβ deposits only in female Tg2576 mice ([@B115]). Compared to men, women receiving statins may lack risk reductions in mortality and stroke ([@B27]). These preclinical and clinical studies imply that statins may also exert a gender-specific effect on AD.

OBESITY, AD, AND STATINS
------------------------

A recent meta-analysis showed that obesity increases the risk of AD \[hazard ratio (HR) 1.80, 95% CI 1.00--3.29; [@B13]\]. Also, it was observed that midlife obesity is associated with an increased risk of some types of cognitive deficit ([@B29]). Statins might have benefits on obesity by increasing the catabolism of several lipids as well as apolipoprotein B-100, a key player in central obesity ([@B175]; [@B109]). Regulation of peroxisome proliferator-activated receptor-α through an isoprenoid pathway also seems to be important for such benefits of statins ([@B130]; [@B80]; [@B117]).

HYPERTENSION, AD, AND STATINS
-----------------------------

Several papers report that midlife hypertension is a risk for AD ([@B151]; [@B82]). This is also supported by recent clinical studies showing that blood pressure-lowering therapy can reduce the risk of AD or dementia ([@B81]; [@B87]). A meta-analysis of randomized controlled trials showed that statins have beneficial effects on hypertension ([@B156]). These effects are additive with those of anti-hypertensive drugs, and occur independently of the baseline and change in cholesterol levels. This suggests the involvement of pleiotropic effects against hypertension-induced systemic inflammation and oxidative insults through the regulation of an isoprenoid pathway, but not blood pressure lowering itself ([@B156]). Further analysis of this effect might reveal a role of statins in the crosstalk between midlife hypertension and AD.

DIABETES, AD, AND STATINS
-------------------------

A recent meta-analysis of 15 prospective cohort studies revealed that diabetes also increases the risk of AD (HR 1.39, 95% CI 1.16--1.66; [@B91]). Interestingly, midlife diabetes seems to accelerate brain aging such as hippocampal atrophy and cognitive decline ([@B104]; [@B29]). It is well known that statin treatment can reduce the risk of coronary artery disease events in patients with diabetes ([@B67]). As the underlying mechanism, regulation of the receptor for advanced glycation end products, RAGE, an important mediator of oxidative and inflammatory processes, might be involved in such statin actions ([@B79]; [@B159]). Of note, RAGE could also be an important target for AD therapy ([@B28]). While a meta-analysis of sub-analysis showed that statins very weakly increase the risk of diabetes itself (HR 1.09, 95% CI 1.02--1.17; [@B138]), J-PREDICT (Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance), an only cohort study whose primary outcome was onset of diabetes, showed a reduction of incidence of diabetes in statin-treated group ([@B106]). Therefore, these findings suggest that diabetes may lie as a confounding factor between statins and AD. Further analysis is required to access the effect of stain on the incidence of diabetes, then on that of AD in pre-diabetic and diabetic patients.

MECHANISMS OF ACTION
====================

EFFECTS OF STATINS ON CHOLESTEROL
---------------------------------

Several groups have reported that cholesterol-lowering drugs, besides statins, decrease Aβ production, while cholesterol itself increases Aβ production in cell culture and animal studies ([@B122]; [@B148]; [@B124]; [@B72]; [@B146]; [@B174]). Therefore, cholesterol-lowering could have a possible preventive effect against the onset of AD, though the role of cholesterol in AD remains unknown in humans. First, it is controversial whether the systemic cholesterol level is relevant to the incidence or the progression of AD ([@B61]; [@B187]; [@B105]; [@B132]; [@B39]; [@B71]; [@B161]; [@B133]). Brain cholesterol or derivative level is also inconsistent among studies using AD brains ([@B158]; [@B154]; [@B101]; [@B113]; [@B140]; [@B164]; [@B171]; [@B26]; [@B32]; [@B76], [@B75]; [@B83]; [@B170]). One of the aims of these observations is the determination of optimal cholesterol levels for the prevention of AD. Some studies reported that a high systemic cholesterol level or high-density lipoprotein (HDL) cholesterol level is associated with longevity and is also protective against AD development in very elderly people, suggesting different roles of cholesterol at different ages ([@B178]; [@B126]). It is noteworthy that some statins can increase plasma HDL level ([@B64]). On the other hand, a high midlife serum cholesterol level has been reported to be a risk factor for the incidence of AD or AD-related pathological changes ([@B71]; [@B114]). This was confirmed by a recent meta-analysis ([@B4]). Therefore, the possible preventive effects of statins on AD might be related to regulation of cholesterol metabolism in midlife.

One inevitable point that must be considered is that cholesterol itself seems to be very important for brain function and maintenance ([@B32]; [@B170]). In fact, a marked reduction of cholesterol levels by high doses of statins seems to decrease neurotropic support and prove toxic for neurons ([@B40]; [@B157]). This might correspond with some case reports and prospective studies observing adverse effects of statins, particularly brain-permeable simvastatin and strong cholesterol-lowering atorvastatin, on cognitive function in especially elderly patients with dementia ([@B173]; [@B38]; [@B112]). Following these reports, the U.S. Food and Drug Administration (FDA) recently added safety warnings to statins concerning confusion and memory loss. Such potential adverse effects on cognitive function should be clarified for the appropriate application of statins for AD prevention or treatment.

ApoE, one of the essential players regulating brain cholesterol metabolism, is the strongest genetic risk factor for AD ([@B7]). The *APOE*-ε4 allele increases the accumulation of senile plaques in AD patients as well as in cognitively normal people ([@B125]; [@B100]). In the periphery, apoE, mainly secreted from the liver, regulates systemic cholesterol metabolism, and is related to dyslipidemia and arteriosclerosis ([@B74]; [@B73]). In *APOE*-ε4 carriers, plasma LDL cholesterol levels are around 10% higher, due to differences in apoE distribution in cholesterol-lipid particles and the metabolism of apoE-containing lipid particles ([@B25]; [@B92]). Therefore, such increase of plasma cholesterol level in *APOE*-ε4 carriers might be a target for prevention of AD. In the brain, apoE plays important roles in brain function through lipid transport as HDL-like particles ([@B121]; [@B62]; [@B17]; [@B43]; [@B172]; [@B180]; [@B169]). We showed that statin treatment increased LDLR-related protein 1 (LRP1, one of the apoE receptors)-mediated clearance of Aβ ([@B147]). Interestingly, a prospective study reported that the risk reduction of AD by statins was observed only in subjects with the *APOE*-ε4 allele ([@B84]). On the other hand, *APOE*-ε4 carriers seem to be less responsive to statins in the regulation on lipids ([@B55]). Therefore, these studies might suggest a possible action of statins on amyloid burden through modulation of the apoE-cholesterol pathway.

PLEIOTROPIC EFFECTS OF STATINS
------------------------------

### Oxidative stress, inflammatory stress, and statins

Oxidative stress and inflammation are thought to be tightly linked to the pathogenesis and development of AD ([@B193]; [@B120]; [@B11]; [@B50]; [@B57]). More importantly, many epidemiological studies suggest that anti-oxidative drugs and anti-inflammatory drugs may reduce the risk of AD. One randomized clinical trial suggested that anti-oxidative drugs (vitamin E and selegiline) might slow the progression of AD ([@B137]). However, a recent randomized clinical trial failed to show any beneficial effect of vitamin E on the conversion of mild cognitive impairment (MCI) to AD ([@B119]). Controversy also exists among the results of randomized prevention trials of anti-inflammatory drugs ([@B166]; [@B93]; [@B45]; [@B152]). A randomized trial even reported an increased risk of AD using celecoxib and naproxen, a Cox-2 inhibitor, in people aged 70 years or older ([@B93]). This implies that anti-inflammatory drugs may worsen AD by reducing some kind of beneficial inflammation for AD ([@B1]; [@B184]), or, as an elderly community-based cohort study suggested, the increased incidence of AD in later life in anti-inflammatory drug users during midlife may reflect delayed effects of the onset of AD ([@B16]). Thus, it remains undetermined whether anti-oxidative or anti-inflammatory drugs are beneficial if administered years before the onset of AD, as with statins.

As noted earlier, several papers showed that an isoprenoid-dependent mechanism of statins is involved in their anti-oxidative and anti-inflammatory effects. Reactive oxygen species are attenuated via the regulation of NADPH by statins ([@B103]). Statins can also modulate several inflammatory responses via peroxisome proliferator-activated receptor-α and -γ and nuclear factor-kappa B ([@B89]; [@B118]). In an AD animal study, simvastatin reduced oxidative stress and inflammation in amyloid precursor protein (APP) transgenic mice ([@B168]). It was also shown that fluvastatin reduced oxidative damage and ameliorated neuronal degeneration and cognitive dysfunction in AD model mice ([@B78]). These studies suggest that a possible mechanism of the preventive action of statins against AD involves anti-oxidative and anti-inflammatory effects via an isoprenoid-dependent pathway.

### Effects of statins in vasculature

Vascular impairment is one aspect of AD. Pathologically impaired vessels have been observed in the brain of AD patients, as represented by cerebral amyloid angiopathy (CAA). The formation of CAA might be promoted by impairment of vascular flow ([@B165]; [@B177]). Furthermore, neurovascular coupling, which controls cerebral blood flow in response to neuronal function, is thought to be involved in the development of AD ([@B56]).

Dysfunction of neurovascular coupling can be reversed by anti-oxidative drugs and anti-inflammatory drugs ([@B56]). In the Rotterdam study, the HR of AD was reduced by all statins, regardless of their lipophilicity ([@B48]). Therefore, the preventive action of statins on AD could be due to their effects on brain blood vessels, as hydrophilic statins act more dominantly on vessels rather than cells inside the brain. Even a lipophilic statin, simvastatin, improved neurovascular dysfunction in an AD mouse model, by attenuating oxidative stress and inflammation. Importantly, such reversal of neurovascular dysfunction was associated with improvement of short- and long-term memory ([@B168], [@B167]). An isoprenoid-dependent effect is involved in increasing the endothelial nitric oxide synthase (eNOS) level via the PI3K/Akt pathway, which is important for vascular function and maintenance ([@B191]). [@B88] showed that simvastatin increased the levels of Akt, phosphorylated, Akt and eNOS, and reversed learning deficits in Tg2576 mice, independently of Aβ deposition. [@B77] also reported that atorvastatin and pitavastatin protected against degenerations of neurovascular units and reversed learning deficits in Tg2576 mice. In addition, regulation of systemic cholesterol by statins might play important roles on prevention of AD by the reduction of cerebrovascular atherosclerosis, which is reported to correlate with AD pathology, including senile plaques and CAA ([@B9]; [@B186]). These studies suggest that one of the important actions of statins with regards to AD could involve blood vessels in the brain.

### Aβ metabolism and statins

The Religious Orders Study, a longitudinal clinical pathologic study, observed that statin users, especially those using lipophilic statins, are less likely to have amyloid load in the brain of old Catholic clergy at autopsy ([@B6]). Another study also showed that cognitively normal people who used statins have fewer amyloid plaques at autopsy ([@B85]). The mechanism by which statins regulate Aβ metabolism in the brain is still not fully clarified yet. As with other proteins, the level of Aβ is determined by the balance of its production and clearance. Blood vessels in the brain play an important role in the regulation of Aβ clearance ([@B10]; [@B177]). Especially, LRP1 could be involved in Aβ clearance by brain blood vessels ([@B10]). Our recent observations showed that fluvastatin increased Aβ clearance from the brain through up-regulating LRP1 level in the brain vessels of wild-type and APP transgenic mice. The notion that statins increase LRP1-mediated Aβ clearance was also supported by an *in vitro* model of Aβ clearance, using human brain blood vessel cells. In addition, an isoprenoid-dependent pathway mediates this effect ([@B147]). These results provide evidence that brain vessels may be directly involved in statins' action on Aβ metabolism. Additional studies using conditional LRP1-knockout mice could clarify the involvement of LRP1 in the enhancement of Aβ clearance by statins ([@B66]). It was also shown that statins increased Aβ clearance by up-regulating insulin degrading enzyme, an Aβ-degrading enzyme *in vitro* ([@B160]). Taking these findings together, statins could restore Aβ clearance, which is reported to be decreased in AD patients ([@B98]).

Many groups also reported that statins regulate Aβ production, although different mechanisms are proposed. Possible mechanisms include regulation of shedding by α/β/γ-secretase, APP-trafficking, or degradation of APP-CTFs (C-terminal fragments of APP) through a cholesterol-dependent or isoprenoid-dependent mechanism ([@B72]; [@B19]; [@B116]; [@B111]; [@B129]; [@B182]; [@B192]; [@B47]). Notably, these proposed mechanisms are all based on *in vitro* culture experiments or animal experiments with high doses of statins. Therefore, the effect of statins *in vivo*, at clinically relevant doses, has yet to be uncovered. Fluvastatin treatment at clinically relevant doses reduced Aβ production by up-regulating the lysosomal degradation of APP-CTFs in the brain of young C57BL/6 mice. This effect was mediated by an isoprenoid-dependent pathway, similarly to the up-regulation of LRP1. Changes in the intracellular distribution of APP-CTFs and small GTPases, Rab5 and Rab7 might be explored to further elucidate the mechanisms of this effect ([@B147]). This result seems to be important, as fluvastatin, one of the brain-impermeable hydrophilic statins, also can modulate the Aβ production pathway in the brain at a clinical dosage. This effect might be mediated by the partial inhibition of small GTPases, as [@B111] indicated.

### Tau metabolism and statins

Another key target for AD might be NFTs, where tau is hyperphosphorylated and forms a filamentous structure. The degree of neuronal loss and the severity of dementia correlate with the accumulation of NFT rather than senile plaques in AD ([@B15]; [@B5]). Several types of dementia, known as tauopathies, also manifest NFT and neuronal loss ([@B31]). Regardless of whether NFT is a subsequent, parallel or separate event to Aβ accumulation, NFT could be an important target for prevention and treatment of AD ([@B153]; [@B59]). Statins were reported to reduce NFT more significantly than senile plaques in cognitively normal subjects ([@B85]). This observation suggests that statins could prevent tau accumulation more readily than Aβ accumulation.

Impaired cholesterol metabolism as well as oxidative and inflammatory stress seems to be involved in tau hyperphosphorylation ([@B139]; [@B70]; [@B99]; [@B107]; [@B95]). Atorvastatin suppressed tau hyperphosphorylation induced by excess cholesterol in the rat brain ([@B90]). On the other hand, [@B14] found that simvastatin and atorvastatin reduced NFT and improved cognitive impairment in a tauopathy mouse model, associated with reduced inflammation. However, of note, cell culture studies showed that high doses of statins cause tau phosphorylation and cell toxicity ([@B52]; [@B4]). These findings suggest that optimal doses of statins may prevent tau hyperphosphorylation and NFT accumulation via both cholesterol- and isoprenoid-dependent effects. Although a study reported that 40 mg/day simvastatin decreased the phospho-tau level in patients with dyslipidemia without dementia ([@B127]), other studies reported that statins including 20--80 mg/day simvastatin failed to show a decrease of phospho-tau or total tau level in the cerebrospinal fluid (CSF) in AD patients ([@B150]; [@B52]; [@B141]) and middle-aged adults with risk of AD ([@B21]). Taken together, further clinical studies should determine the optimal doses of statins, taking individual disease stage into account.

### Other genetic factors and statins

In addition to the *APOE* gene, recent genome-wide association studies (GWAS) identified novel risk genes for AD ([@B108]). These genes include box-dependent myc-interacting protein 1 (BIN1), clusterin (CLU, also called apolipoprotein J), ATP-binding cassette transporter A7 (ABCA7), complement component receptor 1 (CR1), phosphatidylinositol-binding clathrin assembly protein (PICALM), and CD33. As BIN1 and PICALM are involved in intracellular trafficking at synapses, these genes might modulate APP trafficking or tau metabolism ([@B185]; [@B22]). CR1 and CD33 are key molecules in inflammatory cells, such as microglia ([@B23]; [@B46]). CLU and ABCA7 are thought to play important roles in lipid homeostasis ([@B163]; [@B188]). [@B68] showed that ABCA7 inactivation in macrophages reduced phagocytic clearance of Aβ and exaggerated Aβ accumulation in mice. Interestingly, statins are reported to enhance ABCA7-dependent phagocytosis through the SREBP pathway ([@B162]). These studies suggest crosstalk between statins and ABCA7 in Aβ metabolism. As these genetic factors are involved in Aβ metabolism, tau metabolism, inflammation, and lipid metabolism, statins may also have crosstalk with these molecules.

FURTHER STUDY OF PREVENTIVE EFFECT OF STATINS FOR AD
====================================================

Whether or not statins are effective for preventing AD is yet to be confirmed. Our study showed a modest effect of a statin on Aβ metabolism in C57BL/6 mice and APP transgenic mice (around 20% reduction of Aβ level in brain; [@B147]). We also observed that 3 months' treatment with fluvastatin (before abundant Aβ plaque deposition) ameliorated impairment of spatial learning performance in APP/PS1 mice (Shinohara et al., unpublished results). These effects are most likely mediated by an isoprenoid-dependent pathway ([@B88]). As cholesterol level is not readily affected by statins in rodents ([@B37]), larger animal models would also be required to demystify the cholesterol-dependent effects of statins ([@B102]).

A surrogate marker for the regulation of Aβ metabolism as well as other AD-associated abnormalities would help to successfully establish preventive effects on AD. Our preliminary animal studies failed to show that statin treatment affects Aβ levels in the blood and CSF (unpublished data), whereas brain Aβ level was reduced by a statin ([@B147]). These experimental results are consistent with the results of clinical studies, reporting no change in Aβ levels in CSF and plasma by statin use in AD patients and cognitively normal adults ([@B58]; [@B150]; [@B53], [@B51]; [@B127]; [@B21]; [@B141]). These results suggest that Aβ levels in CSF and plasma would not reflect the "anti-Aβ" effect of statins in the brain. Therefore, amyloid- and tau-PET (positron emission tomography) imaging ([@B96]; [@B176]), and other potential CSF surrogate markers like soluble form of LRP1 ([@B134], [@B135]) -- might be helpful. Several markers of oxidative stress, inflammation, or vascular plasticity and integrity could be assessed to define the beneficial preventive action of statins against AD.

As mentioned above, statins might transiently impair cognitive function ([@B110]; [@B69]; [@B173]), especially where the drug is firstly administered to treat patients aged over 75 years. This adverse effect remains a rare occurrence ([@B131]). Considering their beneficial effects, statins should be used with close attention to the emergence of adverse effects in elderly patients.

CONCLUSION
==========

This review describes the probable preventive actions of statins on AD. These effects could be achievable if statins were administered decades before the onset of AD or from midlife. Such effects, if present at all, could be negligible, with a 10--50% reduction in risk being expected from the positive results of clinical studies. The preventive effects of statins on AD include the regulation of Aβ metabolism, tau metabolism, cholesterol metabolism, oxidative and inflammatory stress, and vascular plasticity and integrity, all of which are independently/interdependently involved in the pathogenesis of AD (**Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**). At least some of these effects could be mediated by regulation of the isoprenoid pathway. Therefore, exploring the mechanisms by which isoprenoid metabolism influences AD pathogenesis may clarify the isoprenoid-dependent effects of statins on AD ([@B35]). Overall, these findings reviewed here suggest that administration of statins in midlife might prevent AD in late life by modifying genetic and non-genetic risk factors for AD (**Figure [1](#F1){ref-type="fig"}**). However, it still remains unclear whether statins really prevent AD in prospective well-controlled clinical studies. At least, it should be clarified whether statins inhibit Aβ accumulation, tau pathological features and atrophy in humans. To answer this question, a randomized controlled study using amyloid PET, tau-PET, and magnetic resonance imaging (MRI) would be useful. This clinical evaluation could help us to overcome this devastating disease.

###### 

Summary of presumable beneficial actions of statin use in midlife on AD epidemiological factors.

                                                                                                                                                                       Targets of statins                                                        
  ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------
  Hyperlipidemia   High cholesterol in midlife is a risk for AD ([@B71]; [@B114]; [@B4])                                                                               Plasma LDL-cholesterol level and HDL cholesterol level ([@B64]; [@B44])   --
  *APOE*-ε4        Promotion of Aβ accumulation and down-regulation of brain activity ([@B121]; [@B62]; [@B17]; [@B43]; [@B125]; [@B100]; [@B172]; [@B180]; [@B169])   Plasma LDL-cholesterol ([@B121])                                          --
  Obesity          Obesity is a risk for AD, and midlife obesity promotes brain aging ([@B27]; [@B13])                                                                 Plasma LDL, HDL, and apoB ([@B175]; [@B109])                              PPAR-α ([@B130]; [@B80])
  Hypertension     Midlife hypertension is a risk for AD ([@B151]; [@B82])                                                                                             --                                                                        eNOS, endothelin-1, and ROS ([@B156])
  Diabetes         Diabetes is a risk for AD, and also midlife diabetes promotes brain aging ([@B91]; [@B104]; [@B29])                                                 --                                                                        RAGE, PPAR-α, -γ, NF-κB, and ROS ([@B79]; [@B159])

Aβ, β-amyloid peptides; AD, Alzheimer's disease; apoB, apolipoprotein B-100; apoE, apolipoprotein E; eNOS, endothelial nitric oxide synthase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NF-κB, nuclear factor-κB; PPAR, peroxisome proliferator-activated protein; RAGE, receptor for advanced glycation end products; ROS, reactive oxygen species.

###### 

Summary of presumable beneficial actions of statin use in midlife on AD pathogenic stress and molecules.

                                             Clinical evidence                                                  Targets of statins                                                                          
  ------------------------------------------ ------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Oxidative stress and inflammatory stress   Oxidative stress and inflammatory stress are involved in AD        --                                                                                          Rac1-NADPH and PPAR-α, -γ and NF-κB ([@B103]; [@B89]; [@B118]; [@B78]; [@B168])
  Vascular system                            Midlife vascular risk factors potentiate development of AD         Cholesterol-induced cerebrovascular atherosclerosis                                         PI3K/Akt/eNOS pathway ([@B88]; [@B191]; [@B167])
  Tau accumulation                           Tau starts to accumulate decades before the onset of AD ([@B59])   Cholesterol-induced tau hyperphosphorylation ([@B90])                                       Cholesterol-independent anti-inflammatory effects ([@B14])
  Aβ accumulation                            Aβ starts to accumulate decades before the onset of AD ([@B60])    Cholesterol-involving Aβ production ([@B122]; [@B148]; [@B124]; [@B72]; [@B146]; [@B174])   APP-CTFs degradation via Rho or Rab family, and Aβ clearance via LRP1 or IDE ([@B111]; [@B147]; [@B160])

Aβ, β-amyloid peptides; AD, Alzheimer's disease; APP-CTFs, C-terminal fragments of amyloid precursor protein; eNOS, endothelial nitric oxide synthase; IDE, insulin degrading enzyme; LRP1, LDLR-related protein 1; NF-κB, nuclear factor-κB; PPAR, peroxisome proliferator-activated protein; Rac1, Ras-related C3 botulinum toxin substrate 1; NADPH, nicotinamide adenine dinucleotide phosphate; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; Akt, v-akt murine thymoma viral oncogene homolog.

![**Possible modification genetic and non-genetic risk factors for AD by statins.** Statins might modify genetic and non-genetic risk factors for Alzheimer's disease (AD). Genetic risk factors for AD include apolipoprotein E and genes involved in intracellular trafficking, lipid metabolism, and inflammation. Non-genetic risk factors include aging, diabetes, dyslipidemia in midlife, hypertension, and inflammation.](fnagi-06-00071-g001){#F1}
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